Review: Risk stratification in the hormonal treatment of patients with prostate cancer

Zoledronic acid in the management of metastatic bone disease

(2016) Thomas Polascik   Therapeutics and Clinical Risk Management

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

(2009) Toni K. Choueiri et al.   CANCER

A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results

(2009) Dominique Prapotnich et al.   WORLD JOURNAL OF UROLOGY

Maximal androgen blockade for advanced prostate cancer

(2008) Laurence Klotz   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer

(2008) Christopher J. DiBlasio et al.   BJU INTERNATIONAL

Metabolic and cardiovascular effects of androgen deprivation therapy

(2008) Payam Hakimian et al.   BJU INTERNATIONAL

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

(2008) Laurence Klotz et al.   BJU INTERNATIONAL

Management of Complications of Prostate Cancer Treatment

(2008) M. D. Michaelson et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer

(2008) Robert W. Ross et al.   CANCER

Cognitive effects of hormone therapy in men with prostate cancer

(2008) Christian J. Nelson et al.   CANCER

Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study

(2008) Gijsberta J. van Londen et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Continuous versus Six Months a Year Maximal Androgen Blockade in the Management of Prostate Cancer: A Randomised Study

(2008) Jacques Irani et al.   EUROPEAN UROLOGY

Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks

(2008) Hendrik Isbarn et al.   EUROPEAN UROLOGY

Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31

(2008) Jason A. Efstathiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Timing of Androgen Deprivation Therapy and its Impact on Survival After Radical Prostatectomy: A Matched Cohort Study

(2008) Sameer A. Siddiqui et al.   JOURNAL OF UROLOGY

Increased Risk of Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

(2008) Polly E Kintzel et al.   PHARMACOTHERAPY

Time to Prostate-Specific Antigen Nadir After Androgen Suppression Therapy for Postoperative or Postradiation PSA Failure and Risk of Prostate Cancer-Specific Mortality

(2008) Christine S. Chung et al.   UROLOGY

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

(2007) Urs E. Studer et al.   EUROPEAN UROLOGY

EAU Guidelines on Prostate Cancer

(2007) Axel Heidenreich et al.   EUROPEAN UROLOGY